Church of PeptidesSearch
Portrait of Cagrilintide
Seeking Canonization · 2020s

Cagrilintide

The Satiety Petitioner

Novo Nordisk, Denmark

Cagrilintide is a long-acting amylin analog being studied for weight management. It has been tested alone and with semaglutide; evidence for the combination CagriSema belongs to a separate treatment record.

Evidence ladder: Controlled human evidenceInvestigational · human trials incompleteEducational record
ClassificationSeeking Canonization
Evidence summaryInvestigational · human trials incomplete
OriginNovo Nordisk, Denmark
Scientific record

What the evidence says

Established role or proposed benefit

  • Long-acting amylin analog studied for weight management.
  • Investigated alone and in combination with semaglutide.

Side effects, risks, and limits

  • Not FDA-approved.
  • Combination benefits, adverse effects, and long-term outcomes remain under study.
Doctide’s verdict

The Satiety Petitioner deserves its own file. Doctide separates the amylin component from its semaglutide partnership, because a promising combination cannot reveal each ingredient’s contribution without the right comparison.

Documented history

Where the real story begins

A phase 2 dose-finding trial published in 2021 evaluated cagrilintide against placebo and liraglutide in adults with overweight or obesity. A separate phase 1b trial published that year investigated coadministration with semaglutide, establishing distinct research paths for the component and combination. Historical source.

Novo Nordisk, Denmark · 2020s
Book of the Canon · comic scripture

The laboratory legend

Cagrilintide arrived with an amylin scroll and asked to sit beside Semaglutide. Doctide reserved the chair but left the canon stamp locked.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. Evidence for cagrilintide alone should be distinguished from evidence for combinations such as CagriSema.

  1. Randomized phase II dose-finding trial, 2021
  2. Cagrilintide with semaglutide phase 1b trial, 2021

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.